首页> 外文OA文献 >Blood-based tumor mutation burden: continued progress toward personalizing immunotherapy in non-small cell lung cancer

【2h】

Blood-based tumor mutation burden: continued progress toward personalizing immunotherapy in non-small cell lung cancer

机译：血液肿瘤突变负担：在非小细胞肺癌中的个性化免疫疗法持续进展

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
引文网络
相似文献
相关主题

著录项

作者
Vincent K. Lam; Jianjun Zhang;
展开▼
作者单位

展开▼
年度 2019
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
中文文献
专利

1. Blood-based tumor mutation burden: continued progress toward personalizing immunotherapy in non-small cell lung cancer [J] . Vincent K. Lam, Jianjun Zhang Journal of Thoracic Disease . 2019,第6期

机译：基于血液的肿瘤突变负担：非小细胞肺癌个性化免疫治疗的持续进展
2. Personalized immunotherapy for non-small cell lung cancer through identification of tumor-specific mutations by next generation sequencing and adoptive transfer of tumor infiltrating lymphocytes that recognize neoantigens [J] . Ken-ichi Hanada, Christopher Chow, Raul Gil Hoyos, Journal for ImmunoTherapy of Cancer . 2015,第S2期

机译：通过下一代测序鉴定肿瘤特异性突变和识别新抗原的肿瘤浸润淋巴细胞的过继转移，从而对非小细胞肺癌进行个性化免疫治疗
3. Tumor mutation score is more powerful than tumor mutation burden in predicting response to immunotherapy in non-small cell lung cancer [J] . Li Yuan, Chen Zuhua, Tao Weiping, Cancer immunology, immunotherapy : . 2021,第8期

机译：肿瘤突变评分比肿瘤突变负担更强大，以预测非小细胞肺癌免疫疗法的反应
4. Association between tumor heterogeneity and progression-free survival in non-small cell lung cancer patients with EGFR mutations undergoing tyrosine kinase inhibitors therapy [C] . Jiangdian Song, Di Dong, Yanqi Huang, Annual International Conference of the IEEE Engineering in Medicine and Biology Society . 2016

机译：接受酪氨酸激酶抑制剂治疗的EGFR突变非小细胞肺癌患者肿瘤异质性与无进展生存的关系
5. The role of NAD(P)H:quinone oxidoreductase 1 in non-small cell lung cancer tumorigenesis and lung cancer stem cell maintenance [D] . Madajewski, Brian. 2016

机译：NAD（P）H：醌氧化还原酶1在非小细胞肺癌的发生和肺癌干细胞维持中的作用
6. Blood-based tumor mutation burden: continued progress toward personalizing immunotherapy in non-small cell lung cancer [O] . Vincent K. Lam, Jianjun Zhang 2019

机译：血液肿瘤突变负担：非小细胞肺癌个性化免疫治疗的持续进展
7. Maximum Somatic Allele Frequency in Combination With Blood-Based Tumor Mutational Burden to Predict the Efficacy of Atezolizumab in Advanced Non-small Cell Lung Cancer: A Pooled Analysis of the Randomized POPLAR and OAK Studies [O] . Yu-tong Chen, Sharvesh Raj Seeruttun, Xiang-yuan Wu, 2019

机译：最大体态等位基因频率与血基肿瘤突变负担的结合预测atezolizumab在先进的非小细胞肺癌中的功效：随机杨树和橡树研究的汇总分析

Blood-based tumor mutation burden: continued progress toward personalizing immunotherapy in non-small cell lung cancer

著录项

引文网络

相似文献

相关主题

期刊订阅